Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: NanoString, Levitas Bio, Bionano Genomics, More

NanoString Technologies nCounter Pro Analysis System

NanoString Technologies launched the nCounter Pro Analysis System. The company said the new system, which has been validated to enable a 21 CFR Part 11 environment, offers simple, fully automated gene expression profiling with direct digital detection. Additionally, cloud-based analytics specific to nCounter Pro data is available through Rosalind, a collaborative data analysis platform, enabling complex data to be more easily managed and analyzed without the need for programming knowledge. The nCounter Pro Analysis System is compatible with NanoString's GeoMx Digital Spatial Profiler.

Levitas Bio LeviCell EOS System

Levitas Bio has launched the LeviCell EOS System, the next generation of its platform for cell separation and enrichment, featuring higher throughput and simultaneous targeted selection of viable cells. Using the company's "levitation" technology, researchers can scale their experiments up to 16X (through up to four interconnected LeviCell ROS modules) and process up to 40 million cells per run. An embedded thermal control system allows users to select from a range of predefined temperatures, ensuring samples are processed at ideal temperatures to maintain cellular states; while a fully reticulated imaging system enables real-time sample characterization analytics during processing, enabling insights such as fractionation, cell counts, viability assessment, and quality measurements, Levitas said.

The company is debuting the platform alongside its new LeviPrep and LeviSelect product lines for tissue dissociation and targeted cellular selection at the upcoming American Association for Cancer Research annual meeting.

Bionano Genomics NxClinical Software Version 6.2

Bionano Genomics released version 6.2 of its NxClinical software. The newest version includes an integrated genomic scar analysis for homologous recombination deficiency, the company said. The feature, developed by BioDiscovery, can be used to measure genomic instability in a platform-agnostic way, allowing cancer researchers to gain insights from genetic data from a range of array and sequencing assays, including several from Illumina, Thermo Fisher Scientific, and AgilentBionano said.

For more new products and services, please visit the New Products page on our website.